Gene · 57721
Papers4,298
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,101 to 1,120 of 4,298
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Little things with significant impact: miRNAs in hepatocellular carcinoma. | Front Oncol | 2023 | 37274242 | PubTator, text mining | PubMed |
| Critical roles of m6A methylation in cardiovascular diseases. | Front Cardiovasc Med | 2023 | 37273867 | PubTator, text mining | PubMed |
| Epigenetic regulation and therapeutic targets in the tumor microenvironment. | Mol Biomed | 2023 | 37273004 | PubTator, text mining | PubMed |
| Tumor-associated macrophages promote cisplatin resistance in ovarian cancer cells by enhancing WTAP-mediated N6-methyladenosine RNA methylation via the CXCL16/CXCR6 axis. | Cancer Chemother Pharmacol | 2023 | 37272931 | PubTator, text mining | PubMed |
| METTL3-dependent m6A methylation facilitates uterine receptivity and female fertility via balancing estrogen and progesterone signaling. | Cell Death Dis | 2023 | 37270544 | PubTator, text mining | PubMed |
| PRMT1 methylates METTL14 to modulate its oncogenic function. | Neoplasia | 2023 | 37269817 | PubTator, text mining | PubMed |
| Mettl14-mediated m6A modification ensures the cell-cycle progression of late-born retinal progenitor cells. | Cell Rep | 2023 | 37269288 | PubTator, text mining | PubMed |
| Enhancer RNAs in transcriptional regulation: recent insights. | Front Cell Dev Biol | 2023 | 37266452 | PubTator, text mining | PubMed |
| m6A‑mediated LINC02038 inhibits colorectal cancer progression via regulation of the FAM172A/PI3K/AKT pathway via competitive binding with miR‑552‑5p. | Int J Oncol | 2023 | 37264959 | PubTator, text mining | PubMed |
| The role of m6A methylation in therapy resistance in cancer. | Mol Cancer | 2023 | 37264402 | PubTator, text mining | PubMed |
| An N6-methyladenosine regulation- and mRNAsi-related prognostic index reveals the distinct immune microenvironment and immunotherapy responses in lower-grade glioma. | BMC Bioinformatics | 2023 | 37264314 | PubTator, text mining | PubMed |
| FLOT1, stabilized by WTAP/IGF2BP2 mediated N6-methyladenosine modification, predicts poor prognosis and promotes growth and invasion in gliomas. | Heliyon | 2023 | 37260902 | PubTator, text mining | PubMed |
| RBM33 is a unique m6A RNA-binding protein that regulates ALKBH5 demethylase activity and substrate selectivity. | Mol Cell | 2023 | 37257451 | PubTator, text mining | PubMed |
| N6-methyladenosine modification of CENPF mRNA facilitates gastric cancer metastasis via regulating FAK nuclear export. | Cancer Commun (Lond) | 2023 | 37256823 | PubTator, text mining | PubMed |
| Smoking-Induced M2-TAMs, via circEML4 in EVs, Promote the Progression of NSCLC through ALKBH5-Regulated m6A Modification of SOCS2 in NSCLC Cells. | Adv Sci (Weinh) | 2023 | 37246269 | PubTator, text mining | PubMed |
| Integrating machine learning and bioinformatics analysis to m6A regulator-mediated methylation modification models for predicting glioblastoma patients' prognosis and immunotherapy response. | Aging (Albany NY) | 2023 | 37244287 | PubTator, text mining | PubMed |
| Protocol for identification and validation of IGF2BP1 target genes in pluripotent human embryonic carcinoma cells. | STAR Protoc | 2023 | 37243602 | PubTator, text mining | PubMed |
| Identification of m7G-Related LncRNA Signature for Predicting Prognosis and Evaluating Tumor Immune Infiltration in Pancreatic Adenocarcinoma. | Diagnostics (Basel) | 2023 | 37238181 | PubTator, text mining | PubMed |
| IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma. | Sci Rep | 2023 | 37236993 | PubTator, text mining | PubMed |
| Pre-mRNA splicing and its cotranscriptional connections. | Trends Genet | 2023 | 37236814 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/57721/papers?page=56